Cite
Comparison of long‐term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia‐positive acute lymphoblastic leukemia: A multicenter retrospective study.
MLA
Guan, Fangshu, et al. “Comparison of Long‐term Outcomes between Imatinib and Dasatinib Prophylaxis after Allogeneic Stem Cell Transplantation in Patients with Philadelphia‐positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study.” Cancer (0008543X), vol. 130, no. 12, June 2024, pp. 2139–49. EBSCOhost, https://doi.org/10.1002/cncr.35232.
APA
Guan, F., Yang, L., Chen, Y., Shi, J., Song, X., Lai, X., Lu, Y., Liu, L., Ouyang, G., Zhao, Y., Yu, J., Xu, Y., Lan, J., Fu, H., Zhao, Y., Qiu, X., Zhu, P., Cai, Z., Huang, H., & Luo, Y. (2024). Comparison of long‐term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia‐positive acute lymphoblastic leukemia: A multicenter retrospective study. Cancer (0008543X), 130(12), 2139–2149. https://doi.org/10.1002/cncr.35232
Chicago
Guan, Fangshu, Luxin Yang, Yi Chen, Jimin Shi, Xiaolu Song, Xiaoyu Lai, Ying Lu, et al. 2024. “Comparison of Long‐term Outcomes between Imatinib and Dasatinib Prophylaxis after Allogeneic Stem Cell Transplantation in Patients with Philadelphia‐positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study.” Cancer (0008543X) 130 (12): 2139–49. doi:10.1002/cncr.35232.